Premium
Radiochemical synthesis and preliminary evaluation of anti‐bladder cancer monoclonal antibody BDI‐1 labeled with rhenium‐188
Author(s) -
Wang Rongfu,
Zhang Chungli,
Yu Lizhang,
Guo Yifeng,
Bai Ying
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.470
Subject(s) - chemistry , rhenium , radioimmunotherapy , monoclonal antibody , in vivo , bifunctional , chelation , radiochemistry , technetium , chromatography , antibody , nuclear chemistry , biochemistry , organic chemistry , immunology , microbiology and biotechnology , biology , catalysis
The anti‐human bladder cancer monoclonal antibody BDI‐1 was radio‐labeled with rhenium‐188 by direct labeling methods using SnCl 2 as reductant and MDP as stannous stabilizer or by indirect method using NHS‐ECM ester as bifunctional chelator. Radiochemical yields of 30±7.23% and 87.4±5.67% and radiochemical purity of more than 95% were achieved. The inmmunoreactive fraction was 58.7%. The results showed that radionuclide 188 Re might be employed using the same labeling methodology with 99m Tc labeling of BDI‐1 for radiommunoimaging (RII) and radioimmunotherapy (RIT) and that may be useful in radioimmunodetection and RIT of human bladder carcinoma in vivo. Copyright © 2001 John Wiley & Sons, Ltd.